Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome
Launched by UNIVERSITY OF PADOVA · Aug 26, 2008
Trial Information
Current as of June 09, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with cirrhosis and diagnosis of HRS type 1 or 2,serum creatinine \> 2.5 mg/dl
- Exclusion Criteria:
- • Diagnosis of HCC with a staging beyond the Milan Criteria di Milano
- • Septic shock (systolic arterial pressure \< 90 mmHg
- • Significant heart or respiratory failure
- • Peripheral arteriophaty clinically significant
- • Previous heart stroke or significant alteration of the ECG
About University Of Padova
The University of Padova, a prestigious research institution in Italy, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university fosters an environment conducive to the development of novel therapies and treatment modalities. Its commitment to ethical standards, patient safety, and scientific rigor ensures that all clinical trials are conducted with the highest level of integrity. Through these initiatives, the University of Padova aims to contribute significantly to the global medical community and improve health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Padova, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials